Kura Oncology Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology or view top-rated stocks.

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Kura Oncology.

Kura Oncology, Inc. (NASDAQ:KURA) announced its earnings results on Thursday, May, 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04.
View Kura Oncology's earnings history.

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, KURA stock has increased by 127.8% and is now trading at $21.98.
View which stocks have been most impacted by COVID-19.

9 brokerages have issued 12-month target prices for Kura Oncology's stock. Their forecasts range from $33.00 to $56.00. On average, they anticipate Kura Oncology's stock price to reach $42.56 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price.
View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts.

Some companies that are related to Kura Oncology include Ionis Pharmaceuticals (IONS), I-Mab (IMAB), TG Therapeutics (TGTX), Schrödinger (SDGR), Legend Biotech (LEGN), Reata Pharmaceuticals (RETA), Allakos (ALLK), Apellis Pharmaceuticals (APLS), Galapagos (GLPG), Blueprint Medicines (BPMC), Hypera (HYPMY), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA) and Turning Point Therapeutics (TPTX).
View all of KURA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Kura Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.88%), EcoR1 Capital LLC (5.57%), Ameriprise Financial Inc. (3.73%), Holocene Advisors LP (3.38%), Victory Capital Management Inc. (2.52%) and BVF Inc. IL (2.47%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

KURA stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Credit Suisse AG, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Federated Hermes Inc., D. E. Shaw & Co. Inc., Acuta Capital Partners LLC, and JPMorgan Chase & Co.. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology or view top insider-selling stocks.

KURA stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Ameriprise Financial Inc., Holocene Advisors LP, Suvretta Capital Management LLC, BVF Inc. IL, BlackRock Inc., Ghost Tree Capital LLC, and Sphera Funds Management LTD..
View insider buying and selling activity for Kura Oncology or or view top insider-buying stocks.

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KURA stock can currently be purchased for approximately $21.98.

Kura Oncology has a market capitalization of $1.46 billion. The company earns $-89,630,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

Kura Oncology employs 93 workers across the globe.

The official website for Kura Oncology is www.kuraoncology.com.

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]